natgillin/translations-raw huggingface dataset:
6 months, respectively: ACR 50: etanercept 41% and 40%, placebo 8% and 5% at months 3 and 6, respectively; p < 0.01 etanercept vs. placebo at all timepoints for both ACR 20 and ACR 50 responses).
3 odnosno 6 mjeseci; ACR 50: etanercept 41% i 40%, placebo 8% i 5% nakon 3, odnosno 6 mjeseci; p < 0,01 etanercept u odnosu na placebo u svim vremenskim točkama za ACR 20 i ACR 50 odgovore).
6 months.
6 mjeseci.
6 observed mainly in patients with prior cardiac condition and/or cardiotoxic chemotherapy and were mostly associated with IRRs
6 Primijećeno najčešće u bolesnika s prethodnim srčanim poremećajima i/ili kardiotoksičnom kemoterapijom i najčešće vezano uz reakcije povezane s infuzijom.
6 or 12 mg**
6 ili 12 mg
6 or 12 months N=594
6 ili 12 mjeseci N=594
6 or 12 months N=602
6 ili 12 mjeseci N=602
6 p-value = 0.0063 (between group comparisons significant at α = 0.05)
6p-vrijednost = 0,0063 (usporedba između skupina značajna je ako je α = 0,05)
6 pens of 3 ml.
6 brizgalica od 3 ml.
6 pipettes
15 pipete
6 pipettes
6 pipeta
6 pipettes
6 pipete
6 pipettes
Pakovanje
6 plungers
6 klipova
6 pre-filled
6 napunjenih brizgalica +
6 pre-filled
6 napunjenih štrcaljki
6 pre-filled
napunjenih štrcaljki
6 pre-filled pen (0.4 ml sterile solution), each with 1 alcohol pad, in a blister.
6 napunjenih brizgalica (0,4 ml sterilne otopine), svaka s 1 jastučićem natopljenim alkoholom, u blisteru.
6 pre-filled pen (0.8 ml sterile solution), each with 1 alcohol pad, in a blister.
6 napunjenih brizgalica (0,8 ml sterilne otopine), svaka s 1 jastučićem natopljenim alkoholom, u blisteru.
6 pre-filled pens
6 napunjenih brizgalica
6 pre-filled pens
brizgalice
6 pre-filled pens RebiDose
6 napunjenih brizgalica RebiDose
6 pre-filled pens, each containing 40 mg adalimumab 6 alcohol pads
6 napunjenih brizgalica, svaka sadrži 40 mg adalimumaba 6 jastučića natopljenih alkoholom
6 pre-filled syringes
6 napunjenih
6 pre-filled syringes
EU/1/07/431/078
6 pre-filled syringes (0.4 ml sterile solution), each with 1 alcohol pad, in a blister.
6 napunjenih štrcaljki (0,4 ml sterilne otopine), svaka s 1 jastučićem natopljenim alkoholom, u blisteru.
6 pre-filled syringes (0.8 ml sterile solution), each with 1 alcohol pad, in a blister.
6 napunjenih štrcaljki (0,8 ml sterilne otopine), svaka s 1 jastučićem natopljenim alkoholom, u blisteru.
6 pre-filled syringes of 0.3 ml
6 napunjenih štrcaljki od 0,3 ml
6 pre-filled syringes of 0.4 ml
6 napunjenih štrcaljki od 0,4 ml
6 pre-filled syringes of 0.5 ml
6 napunjenih štrcaljki od 0,5 ml
6 pre-filled syringes of 0.5 ml
6 napunjenih štrcaljki od 0,5ml
6 pre-filled syringes of 0.6 ml
6 napunjenih štrcaljki od 0,6 ml
6 pre-filled syringes of 0.7 ml
6 napunjenih štrcaljki od 0,7 ml
6 pre-filled syringes of 0.75 ml
6 napunjenih štrcaljki od 0,75ml
6 pre-filled syringes of 0.8 ml
6 napunjenih štrcaljki od 0,8 ml
6 pre-filled syringes of 0.9 ml
6 napunjenih štrcaljki od 0,9 ml
6 pre-filled syringes of 1 ml
6 napunjenih štrcaljki od 1 ml
6 pre-filled syringes of 1 ml
6 napunjenih štrcaljki od 1ml
6 pre-filled syringes of Rebif 22 micrograms
6 napunjenih štrcaljki lijeka Rebif 22 mikrograma
6 pre-filled syringes of Rebif 8.8 micrograms
6 napunjenih štrcaljki lijeka Rebif 8,8 mikrograma
6 pre-filled syringes with safety needle containing 0.5 ml.
6 napunjenih štrcaljki sa sigurnosnom iglom koje sadrže 0,5 ml
6 pre-filled syringes, each containing 40 mg adalimumab 6 alcohol pads
6 napunjenih štrcaljki, svaka sadrži 40 mg adalimumaba 6 jastučića natopljenih alkoholom
6 Primary analysis was performed with a data cut-off date of 12 December 2012 and is considered the final analysis
6 Primarna analiza provedena je na temelju podataka prikupljenih do 12. prosinca 2012. i smatra se završnom analizom
6 single dose vials, 6 injection syringes of 1 mL, 6 injection needles and 6 cleansing swabs
6 jednodoznih bočica, 6 štrcaljki za injekciju od 1 ml, 6 igala za injekciju i 6 tupfera za čišćenje
6 single dose vials, 6 injection syringes of 2 mL, 6 injection needles and 6 cleansing swabs
6 jednodoznih bočica, 6 štrcaljki za injekciju od 2 ml, 6 igala za injekciju i 6 tupfera za čišćenje
6 spot-on applicators
6 aplikatora za nakapavanje
6 spray containers
6 jednodoznih spremnika
6 tablets (1 blister strip)
6 tableta (1 blister traka)
6 tablets MIRAPEXIN
6 tableta MIRAPEXIN
6 The higher incidence of back pain during infusion in the Visudyne group was not associated with any evidence of haemolysis or allergic reaction and usually resolved by the end of the infusion.
6 Veća incidencija boli u leđima tijekom infuzije u skupini koja je primala Visudyne nije bila povezana ni sa kojim znakom hemolize ni alergijske reakcije, a do kraja infuzije bol bi obično prošla.
6 This adverse reaction was identified through post-marketing surveillance for emtricitabine but was not observed in randomised controlled clinical studies in adults or paediatric HIV clinical studies of emtricitabine.
6 Ova nuspojava prepoznata je tijekom praćenja lijeka emtricitabina nakon stavljanja u promet, ali nije bila opažena u randomiziranim kontroliranim kliničkim ispitivanjima emtricitabina u odraslih ili u kliničkim ispitivanjima emtricitabina u pedijatrijskih bolesnika zaraženih HIV-om.
6 This was a rare adverse reaction for tenofovir disoproxil fumarate.
6 Ovo je bila rijetka nuspojava tenofovirdizoproksilfumarata.
6 to 11
6 do 11
6 to 11 months N = 19 N = 15
6 do 11 mjeseci N = 19 N = 15
6 to 17 Y
od 6 do 17 G
6 to 35 M
od 6 do 35 M
6 to 59 M
od 6 do 59 M
6 to 71 M
od 6 do 71 M
6 to < 12
6 do < 12
6 to < 12 months
6 do < 12 mjeseci
6 to < 12 years
6 do < 12 godina
6 to < 12 years ETR
6 do<12 godina ETR
6 to < 17 years
6 do < 17 godina
6 to < 18 years ETR
6 do<18 godina ETR
6 to <12 y
6 do
6 to <12 years
od 6 do <12 godina
6 to less than 12
6 do manje od 12
6 to less than 8
od 6 do manje od 8
6 vial
6 bočica
6 vials
6 bočice
6 vials + 6 ampoules
6 bočica + 6 ampula
6 vials + 6 injection syringes + 6 injection needles + 6 cleansing swabs
6 bočica + 6 štrcaljki za injekciju + 6 igala za injekciju + 6 tupfera za čišćenje
6 vials of powder for solution for injection and 6 ampoules of solvent for injection;
6 bočica s praškom za otopinu za injekciju i 6 ampula s otapalom za injekciju;
6 vials of powder for solution for injection and 6 ampoules of solvent for parenteral use.
6 bočica s praškom za otopinu za injekciju i 6 ampula s otapalom za parenteralnu primjenu;
6 Wait for 3 minutes until the dispersible tablets have completely broken apart.
6 Pričekajte 3 minute dok se tablete za oralnu suspenziju u potpunosti ne rastope.
6 Week Follow-up
nakon 6 tjedana praćenja
6 weeks (42 days)
6 tjedana (42 dana)
6 weeks after opening the bottle.
6 tjedana nakon otvaranja bočice.
6 weeks after your 1st treatment
6 tjedana nakon 1. doze
6 weeks old), at dosages of three or five times the recommended dose, transient signs attributed to injection site discomfort were observed and included walking backwards, head shaking, rubbing the injection site, lying down and getting up, bleating.
U janjadi (starih približno 6 tjedana), prilikom doziranja od tri ili pet puta veće doze od preporučene, zabilježeni su prolazni znakovi pripisani nelagodnom mjestu injiciranja, što uključuje hodanje unatrag, tresenje glavom, trljanje mjesta ubrizgavanja, ležanje i ustajanje, blejanje.
6 weeks old), at dosages of three or five times the recommended dose, transient signs attributed to injection site discomfort were observed, and included walking backwards, head shaking, rubbing the injection site, lying down and getting up, bleating.
U janjadi (starih približno 6 tjedana), prilikom doziranja od tri ili pet puta veće doze od preporučene, zabilježeni su prolazni znakovi pripisani nelagodnom mjestu injiciranja, što uključuje hodanje unatrag, tresenje glavom, trljanje mjesta ubrizgavanja, ležanje i ustajanje, blejanje.
6 x 1 capsule
6 x 1 kapsula
6 x 1 film-coated tablets
6 x 1 filmom obložena tableta
6 x 10 doses (20 ml) 6 x 25 doses (50 ml) 6 x 50 doses (100 ml) 10 x 5 doses (10 ml)
6 x 10 doza (20 ml) 6 x 25 doza (50 ml) 6 x 50 doza (100 ml) 10 x 5 doza (10 ml)
6 x 2.5 mL.
6 x 2,5 ml.
6 years.
6 godina.
6 × 1 tablet in aluminum/Polyethylene Terephthalate (PET)/Paper foil and polyvinyl chloride (PVC)/polyvinylidene chloride (PVdC) clear film perforated child-resistant unit-dose blisters.
6 × 1 tableta u perforiranim blisterima sigurnima za djecu djeljivima na jedinične doze od folije od aluminija/polietilentereftaleata (PET)/papira i prozirnog filma od polivinilklorida (PVC)/polivinilidenklorida (PVdC).
6 – 35 months
6 - 35 mjeseci
6 – 35 months
6 – 35 mjeseci
6% w/v solution
12 % w/v otopina
6% w/v solution
6 % w/v otopina
6) injection needles (multipack)
6) igala (zbirno pakiranje)
6+7 Abdominal pain and gastrointestinal haemorrhage were most commonly observed in GIST patients.
6+7 Bol u abdomenu i gastrointestinalno krvarenje su najčešće uočeni u GIST bolesnika.
6+7 Abdominal pain and gastrointestinal haemorrhage were most commonly observed in GIST patients.
6+7 Bol u trbuhu i gastrointestinalno krvarenje su najčešće uočeni u bolesnika s GISTO-om.
6, 8 months
6, 8 mjeseci
6, boulevard de l'Europe, F-21800 Quétigny, France
6, boulevard de l'Europe, F-21800 Quétigny, Francuska
6, Boulevard de l’Europe F-21800 Quétigny France
6, Boulevard de l’Europe F-21800 Quétigny Francuska
6,000 IU/0.6 ml
6000 IU/0,6 ml
6,000 micrograms/ml.
6 000 mikrograma/ml.
6,000 µg/kg
6.000 µg/kg
6- to 11-year-olds (≥14 kg to <25 kg)
od 6 do 11 godina (≥ 14 kg do < 25 kg)
6- to 11-year-olds (≥14 kg to <25 kg)
od 6 do 11 godina (≥14 kg do <25 kg)
6- to 11-year-olds (≥25 kg)
od 6 do 11 godina (≥ 25 kg)
6- to 11-year-olds (≥25 kg)
od 6 do 11 godina (≥25 kg)
6-10 years
6-10 godina
6-10-14 weeks N= 265 (1 study)
6.-10.-14. tjedan N= 265 (1 ispitivanje)
6-11 months
3-5 godina
6-11 months
6-11 mjeseci
6-12 years
6-12 god.
6-17 years
6-17 godina
6-35 months, 3-8 years and 9-17 years) achieved high levels of antibodies to (A/Vietnam/1194/2004) as evaluated with SRH and HI assays as presented in table below*.
6-35 mjeseci, 3-8 godina i 9-17 godina) postigle su visoke razine protutijela na A/Vietnam/1194/2004 što je procijenjeno SRH i HI analizama, kako je prikazano u tablici u nastavku*.
6-35 months, 3-8 years and 9-17 years) achieved high levels of antibodies to (A/Vietnam/1194/2004) as evaluated with SRH and HI assays as presented in table below*.
6-35 mjeseci, 3-8 godina i 9-17 godina) postigle su visoke razine protutijela na virus (A/Vietnam/1194/2004), što je procijenjeno SRH i HI analizama i prikazano u tablici u nastavku*.
6-35 months, 3-8 years and 9-17 years) achieved high levels of antibodies to (A/Vietnam/1194/2004) as evaluated with SRH and HI assays as presented in table below*.
6-35 mjeseci, 3-8 godina i 9-17 godina) postigle su visoke razine protutijela na virus (A/Vietnam/1194/2004), što je procijenjeno SRH i HI testovima i prikazano u tablici u nastavku*.
6-8 mg/kg/day up to a maximum dose of 500 mg/day.
Doza iznosi od 6 do 8 mg/kg na dan do maksimalne doze od 500 mg na dan.
6-9 and 9-12 month study intervals, respectively.
3 do 6 mjeseci, 6 do 9 mjeseci, odnosno 9 do 12 mjeseci.
6-9 and 9-12 month study intervals, respectively.
44,2) tijekom ispitivanja u intervalima od 0 – 1, 1 – 3, 3 – 6, 6 – 9 odnosno 9 – 12 mjeseci.
6-9 days.
6-9 dana.
6-beta-naltrexol is eliminated more slowly and thus circulates at much higher concentrations than naltrexone.
6-beta-naltreksol se eliminira sporije i stoga cirkulira pri puno višim koncentracijama od naltreksona.
6-mercaptopurine (6–MP) for inflammatory bowel disease.
6-merkaptopurinom (6-MP) za liječenje upalne bolesti crijeva.
6-Minute Walk Distance (m)
Prijeđena udaljenost hodom (m) u 6 minuta
6-Minute walk test (meters)
6-minutni test hodanja (u metrima)
6-month repeat-dose toxicity study in this species) when dams were dosed prior to and during early pregnancy.
6-mjesečnom ispitivanju toksičnosti ponovljene doze provedenom za tu životinjsku vrstu) kad su ženke primale tu dozu prije i tijekom rane faze skotnosti.
6-MP (75 mg/m2/day, PO): days 1-56
6-MP (75 mg/m²/dan, p.o.): dani 1-56
6-MP (75 mg/m2/day, PO): days 11-56 (Withhold 6-MP during the 6-10 days of cranial irradiation beginning on day 1 of Cycle 5.
6-MP (75 mg/m2/dan, p.o.): dani 11-56 (Uskratiti 6-MP tijekom 6-10 dana kranijalne iradijacije dana 1, ciklusa 5.
6-MP (75 mg/m2/day, PO): days 8-28
6-MP (75 mg/m²/dan, p.o.): dani 8-28
6-MP 25 mg/m2 oral, days 1-20
6-MP 25 mg/m2 peroralno, dani 1-20
6-MP 25 mg/m2 oral, days 1-20
6-MP 25 mg/m² peroralno, dani 1-20
6-MP 60 mg/m2 oral, days 26-46
35-38, 42-45; 6-MP 60 mg/m2 peroralno, dani 26-46
6-MP 60 mg/m2 oral, days 26-46
6-MP 60 mg/m2 peroralno, dani 26-46
6-MP 60 mg/m2 oral, days 26-46
6-MP 60 mg/m² peroralno, dani 26-46
6-MP concomitantly with or immediately prior to a TNF-blocker.
6-MP istodobno ili neposredno prije primjene blokatora TNF-a.
6.0 g/day
6,0 g/dan
6.0 mg/dL at the final visit) for patients with a baseline serum urate level of ≥ 10 mg/dL treated with febuxostat 40 mg QD was 27% (66/249), with febuxostat 80 mg QD 49% (125/254) and with allopurinol 300 mg/200 mg QD 31% (72/230), respectively.
<6,0 mg/dl na završnoj kontroli) u CONFIRMS ispitivanju, a kojima je početna razina urata u serumu bila ≥ 10 mg/dl bio je 27% (66/249) kod bolesnika liječenih febuksostatom od 40 mg jednom dnevno, 49% (125/254) kod liječenih febuksostatom od 80 mg jednom dnevno te 31% (72/230) kod bolesnika liječenih alopurinolom 300 mg/200 mg jednom dnevno.
6.0 ml of sodium chloride 0.9%, solution for injection to be able to handle the dosing of small children (see section 4.2 ‘Posology and method of administration – Paediatric population’).
6,0 ml 0,9% otopine za injekciju natrijeva klorida kako bi se provelo doziranje u male djece (vidjeti dio 4.2 ‘Doziranje i način primjene – Pedijatrijska populacija’).
6.0 mmHg with timolol.
6,0 mmHg prilikom primjene timolola.
6.0 to 7.8 log10 CCID*50
6,0 to 7,8 log10 CCID*50
6.0 to 7.8 log10 CCID50
6,0 do 7,8 log10 CCID50
6.1
često
6.1  NR
6,1 - ND
6.2 List of excipients
Popis pomoćnih tvari
6.2 months for the placebo plus vemurafenib arm.
9,9 mjeseci za skupinu koja je primala Cotellic plus vemurafenib, u odnosu na 6,2 mjeseca za skupinu koja je primala placebo plus vemurafenib.
6.2 to 8.0
6,2 do 8,0
6.25 mg/kg body weight every 6 hours.
6,25 mg po kilogramu tjelesne težine svakih 6 sati.
6.27
TT
6.3 months [95% CI 0.395, 0.765].
6,3 mjeseca [95% CI 0,395, 0,765].
6.3% p=0.067 (-0.4, 13.1)
6,3% p=0,067 (-0,4; 13,1)
6.35 log10 IU/ml; 18% had cirrhosis; 25% had HCV genotype 4a, and 73% HCV genotype 4d; 85% had non-CC IL28B alleles (CT or TT); 33% were treatment-naïve, and 68% were treatment-experienced.
genotip 4a, i 73% HCV genotip 4d; 85% imalo je ne-CC IL28B alele (CT ili TT); 33% prethodno nisu bili liječeni, i 68% bili su prethodno liječeni.
6.4 mg (aluminium)
6,4 mg (aluminij)
6.4. Special precautions for storage
6.4. Posebne mjere opreza pri skladištenju
6.4. Special precautions for storage
6.4. Posebne mjere predostrožnosti za čuvanje
6.4. Special precautions for storage
6.4. Posebne mjere pri čuvanju
6.4. Special precautions for storage
Posebne mjere opreza za čuvanje
6.4. Special precautions for storage
Posebne mjere predostrožnosti za čuvanje
6.4. Special precautions for storage
Posebne mjere pri čuvanju
6.4. Special precautions for storage
Posebne mjere pri čuvanju lijeka
6.5 mg/kg granules
6,5 mg/kg granule
6.5 months for the bortezomib monotherapy patients compared with 9.3 months for the Caelyx plus bortezomib combination therapy patients.
Medijan za TTP iznosio je 6,5 mjeseci kod bolesnika liječenih monoterapijom bortezomibom u usporedbi s 9,3 mjeseca kod bolesnika liječenih kombinacijom Caelyxa i bortezomiba.
6.5 years of Replagal 0.2 mg/kg therapy in an open-label long-term extension study in 9 boys.
15 dječaka, a poboljšanje je održano kod 9 dječaka tijekom 6,5 godina liječenja Replagalom 0,2 mg/kg u nastavku otvorenog dugotrajnog ispitivanja.
6.6 (3.29)
(SE)
6.6 (3.8 to 10.5)
6,6 (3,8 do 10,5)
6.6 m vs 5.8 m
6,6 m vs 5,8 m
6.6 MBq/vial at 12 h (CET) ref. date: [DD/MM/YYYY]
6,6 MBq/bočici u 12 h (SEV) na referentni datum: [DD/MM/GGGG]
6.6 Nature and contents of container
Vrsta i sadržaj spremnika
6.6 Special precaution for disposal and other handling
Posebne mjere opreza za zbrinjavanje i druga rukovanja lijekom
6.6 Special precautions for disposal and other handling
6.6 Posebne mjere za zbrinjavanje i druga rukovanja lijejom
6.6 Special precautions for disposal and other handling
Posebne mjere opreza za zbrinjavanje i druga rukovanja lijekom
6.6. Special precautions for disposal
Posebne mjere za zbrinjavanje
6.7 (5.75 to 8.21)
6,9 (6,37 do 7,20)
6.7%, p < 0.001c)
6,7%; p < 0,001c)
6.8 (3.7 to 11.1)
6,8 (3,7 do 11,1)
6.8% to 93.2%
6,8 % do 93,2
6.8% vs 1.0%
6,8% vs 1,0
6.9 m vs 6.9 m p=0.9259
p=0,9259
6.OTHER
DRUGO
60 % (0.6 IU/ml)
60% (0,6 IU/ml)
60 (2 x 30) sachets (multipack)
60 (2 x 30) vrećica (višestruko pakovanje)
60 (2 x 30) sachets (multipack)
60 (2 x 30) vrećice (višestruko pakovanje)
60 - 100 (initial level)
60 – 100 (početna doza)
60 ampoules
60 ampula
60 ampoules (10x6)
60 ampola (10x6)
60 capsules
60 tvrdih kapsula
60 days after first opening.
60 dana nakon prvog otvaranja.
60 film-coated tablets 180 (3 bottles of 60) film-coated tablets
60 filmom obloženih tableta 180 (3 boce sa 60) filmom obloženih tableta
60 film-coated tablets Multipack: 112 (2 packs of 56) film-coated tablets Multipack: 196 (7 packs of 28) film-coated tablets 60x1 film-coated tablets
Višestruko pakiranje: 112 (2 pakiranja s 56) filmom obloženih tableta Višestruko pakiranje: 196 (7 pakiranja s 28) filmom obloženih tableta 60x1 filmom obložena tableta
60 film-coated tablets Scored tablet
60 filmom obloženih tableta Tablete s razdjelnim urezom
60 film-coated tablets Scored tablets
60 filmom obloženih tableta Tablete s razdjelnim urezom
60 film-coated tablets Scored tablets‌
60 filmom obloženih tableta tablete s razdjelnom crtom
60 film-coated tablets.Component of a multipack.
60 filmom obloženih tableta.
60 g granules.
60 g granula.
60 Goswell Road London EC1M 7AD United Kingdom
60 Goswell Road London EC1M 7AD Ujedinjena Kraljevina
60 hard capsules.
60 tvrdih kapsula
60 hard capsules: EU/1/03/267/001
60 tvrdih kapsula: EU/1/03/267/001
60 hard capsules: EU/1/03/267/002
60 tvrdih kapsula: EU/1/03/267/002
60 hard capsules: EU/1/03/267/003
60 tvrdih kapsula: EU/1/03/267/003
60 hard capsules: EU/1/03/267/004
60 tvrdih kapsula: EU/1/03/267/004
60 hours
60. satu
60 mcg/0.3 ml
60 mcg/0,3 ml
60 mg (0.6 ml) twice daily
60 mg (0,6 ml) dva puta na dan
60 mg (3 grey 20 mg capsules)
60 mg (3 sive kapsule od 20 mg)
60 mg capsules EU/1/15/1010/011 EU/1/15/1010/012 EU/1/15/1010/013 EU/1/15/1010/014 EU/1/15/1010/015 EU/1/15/1010/016 EU/1/15/1010/017 EU/1/15/1010/018 EU/1/15/1010/019 EU/1/15/1010/020 EU/1/15/1010/029 EU/1/15/1010/030 EU/1/15/1010/031 EU/1/15/1010/032 EU/1/15/1010/033 EU/1/15/1010/034 EU/1/15/1010/035 EU/1/15/1010/036 EU/1/15/1010/039 EU/1/15/1010/040
60 mg kapsule EU/1/15/1010/011 EU/1/15/1010/012 EU/1/15/1010/013 EU/1/15/1010/014 EU/1/15/1010/015 EU/1/15/1010/016 EU/1/15/1010/017 EU/1/15/1010/018 EU/1/15/1010/019 EU/1/15/1010/020 EU/1/15/1010/029 EU/1/15/1010/030 EU/1/15/1010/031 EU/1/15/1010/032 EU/1/15/1010/033 EU/1/15/1010/034 EU/1/15/1010/035 EU/1/15/1010/036 EU/1/15/1010/039 EU/1/15/1010/040
60 mg hard gastro-resistant capsules
60 mg tvrde želučanootporne kapsule
60 mg once daily
60 mg jedanput na dan
60 mg oseltamivir suspension delivers 1.7 g of sorbitol.
60 mg oseltamivir suspenzije sadrži 1,7 g sorbitola.
60 mg single
Ctrough
60 mg tablet: blue, modified rectangular (major axis 9.9 mm, minor axis 5.6 mm), shallow-convex, debossed with “OTSUKA” and “60” on one side
Tableta od 30 mg: plava, okrugla (promjer: 8 mm), blago konveksna, s utisnutim “OTSUKA” i “30” na jednoj strani.
60 mg/kg/day (10 times the mean steady-state AUC at the maximum recommended human dose).
60 mg/kg/dan (10 puta veća od srednje vrijednosti AUC-a u stanju dinamičke ravnoteže pri maksimalnoj preporučenoj dozi za ljude).
60 mg/m2 oral, days 1-7, 15-21; IDA 9 mg/m2 oral, days 1-28; MTX
60 mg/m2 peroralno, dani 1-7, 15-21; IDA 9 mg/m2 peroralno, dani 1-28;
60 mg/m².
60 mg/m2.
60 micrograms PRE-FILLED SYRINGES LABEL
NALJEPNICA ZA NAPUNJENU ŠTRCALJKU 60 mikrograma
60 million IU solution for injection in multidose pen 1 pen, 12 injection needles and 12 cleansing swabs 2 pens, 24 injection needles and 24 cleansing swabs 8 pens, 96 injection needles and 96 cleansing swabs
60 milijuna IU otopina za injekciju u višedoznoj brizgalici 1 brizgalica, 12 igala za injekciju i 12 tupfera za čišćenje 2 brizgalice, 24 igle za injekciju i 24 tupfera za čišćenje 8 brizgalica, 96 igala za injekciju i 96 tupfera za čišćenje
60 million IU/pen
60 milijuna IU/brizgalica
60 minutes.
60 minuta.
60 ml HDPE bottles with induction-sealed, polypropylene child-resistant caps; 60 film-coated tablets per bottle.
HDPE boce od 60 ml s polipropilenskim sigurnosnim zatvaračem za djecu sa zaštitnom folijom; 60 filmom obloženih tableta po boci.
60 ml infusion bag
Vrećica za infuziju od 60 ml
60 ml or 75 ml*
60 ml ili 75 ml
60 ml plastic bottles capped with child-resistant induction seal closure; 60 film-coated tablets per bottle.
Plastičnim bocama od 60 ml zatvorenima sigurnosnim zatvaračem za djecu sa zaštitnom folijom; 60 filmom obloženih tableta po boci.
60 months 76.4% (70.8-81.5)
60 mjeseci
60 months at 2 °C - 8 °C.
60 mjeseci na temperaturi 2°C–8°C.
60 months at 2°C – 8°C.
60 mjeseci na temperaturi 2°C–8°C.
60 months.
60 mjeseci.
60 patients had a serious infusion reaction and 3 patients reported a possible anaphylactic reaction (2 of which were among the serious infusion reactions).
3 bolesnika prijavila moguću anafilaktičku reakciju (od kojih su 2 bile među ozbiljnim reakcijama na infuziju).
60 pouches
Transdermalni
60 prolonged-release tablets
60 tableta s produljenim oslobađanjem
60 sachets - each sachet contains medicine for a single dose.
60 vrećica – jedna vrećica sadrži dovoljno lijeka za jednu dozu
60 sachets, two 5 ml oral dosing syringes and 2 mixing cups.
60 vrećica, dvije štrcaljke od 5 ml za doziranje kroz usta i 2 čaše za miješanje.
60 single-dose containers
60 jednodoznih
60 sprays
60 potisaka
60 tablets
60 tablet
60 tablets
60 tableta.
60 tablets
60 Tablete
60 tablets
60 tablete s
60 tablets
tableta
60 tablets: EU/1/08/469/003
60 tableta: EU/1/08/469/003
60 tablets: EU/1/08/469/008
60 tableta: EU/1/08/469/008
60 tablets: EU/1/08/469/013
60 tableta: EU/1/08/469/013
60 tablets: EU/1/08/469/018
60 tableta: EU/1/08/469/018
60 tablets: EU/1/08/469/023
60 tableta: EU/1/08/469/023
60 tablets: EU/1/11/721/005
60 tableta: EU/1/11/721/005
60 tablets: EU/1/11/721/012
60 tableta: EU/1/11/721/012
60 tablets: EU/1/11/721/019
60 tableta: EU/1/11/721/019
60 tablets: EU/1/11/723/005
60 tableta: EU/1/11/723/005
60 tablets: EU/1/11/723/012
60 tableta: EU/1/11/723/012
60 tablets: EU/1/11/723/019
60 tableta: EU/1/11/723/019
60 to 70
60 do 70
60 transdermal patches
60 transdermalnih flastera
60 unit doses
60 doza
60 vials of Water for Injections that is used to reconstitute the Fuzeon powder
60 bočica s vodom za injekcije kojom se Fuzeon prašak priprema za primjenu
60 vials powder for solution for injection 60 vials solvent
60 bočica s praškom za otopinu za injekciju 60 bočica s otapalom
60 vials with powder for solution for injection
60 bočica s praškom za otopinu za injekciju
60 x 1 capsules
60 x 1 kapsula
60 x 1 capsules (unit dose)
60 x 1 kapsula (jedinična doza)
60 X 1 film-coated tablet
60 X 1 filmom obloženih tableta
60 x 1 film-coated tablets
60 x 1 filmom obložena tableta
60 x 1 film-coated tablets
60 x 1 filmom obloženih tableta
60 x 1 film-coated tablets.
60 x 1 filmom obložena tableta.
60 x 1 soft capsule
60 x 1 meka kapsula
60 x 1 soft capsule.
60 x 1 meka kapsula.
60 x 1 soft capsules in Aluminium/aluminium perforated unit dose blisters Not all pack sizes may be marketed.
60 x 1 mekih kapsula u aluminij/aluminij perforiranim blisterima djeljivim na jedinične doze Na tržištu se ne moraju nalaziti sve veličine pakiranja.
60 x 1 soft capsules in Aluminium/aluminium perforated unit dose blisters Not all pack-sizes may be marketed.
60 x 1 mekih kapsula u aluminij/aluminij perforiranim blisterima djeljivim na jedinične doze Na tržištu se ne moraju nalaziti sve veličine pakiranja.